Scientific journal
Fundamental research
ISSN 1812-7339
"Перечень" ВАК
ИФ РИНЦ = 1,674

Study of the influence of mexicor on the antiarrhythmic activity of allapinin

Kotlyarov A.A. 1 Dmitrieva O.A. 2 Karyakina T.N. 2 Barabanova L.I. 1
1 Institute Nuclear Power Energy National Research Nuclear University «Moscow Engineering Physics Institute», Obninsk
2 The Mordovian N.P. Ogarev State University, Saransk
Results of research of the combined application antiarrhythmic drag allapinin and a cytoprotector mexicor are presented. 60 patients with various infringements of a rhythm of heart (average age 51,6 ± 1,9 year). To the first group(n = 30) appointed mexicor (300 mg/sut intravenously to 200 ml of an isotonic solution of chloride of sodium) and allapinin (37,5–75 mg/sut per os), the second group (n = 30)– allapinin (37,5–75 mg/sut per os) against basic therapy of the basic disease. It is shown that inclusion in therapy mexicor has led more expressed antiarrhythmic effect in comparison with monotherapy allapinin that was shown as in the relation supraventricular and ventricular arrhythmia.
arrhythmias
allapinin
mexicor
1. Vankova LV Metabolic therapy etilmetilgidroksipiridina succinate with ventricular arrhythmias. Avtoref. yew. edging. medical sciences. Saransk. 2005.
2. Golikov S.P., Mihin V.P., Polumiksov V.Y. etc. Efficiency tsitoprotektora meksikor in urgent cardiology // Therapeutic archive. 2004. Т.76, no. 4. рр. 60tasmania65.
3. Kotlyarov A.A. Metabolic cardioprotection an effective method for prevention of side effects of antiarrhythmic agents. Saransk, 2004. 160 p.
4. Sokolov S.F., Dzhagangirov F.N. Antiarrhytmic preparation allapinin: review of results of clinical studying // Cardiology. 2002, no. 7. рр. 96–102.
5. Sokolov S.F. Results of clinical studying of a preparation allapinin and modern approaches to treatment of patients with violations of a rhythm of heart//the Messenger of an aritmologiya. 2011. no. 64. рр. 60–70.

Рецензенты:

Рахматуллов Ф.К., д.м.н., профессор, заведующий кафедрой внутренних болезней медицинского института Пензенского государственного университета, г. Пенза;

Праскурничий Е.А., д.м.н., профессор кафедры терапии Института последипломного профессионального образования ФМБЦ им. А.И. Бурназяна.

Работа поступила в редакцию 09.10.2012